Discontinued drugs in 2012: Oncology drugs

Expert Opinion on Investigational Drugs

Volumn 22, Issue 12, 2013, Pages 1627-1644

  Williams, Robert ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

AGS 1C4D4; AMG 479; Amuvatinib; AR 67; ASP 9521; AZD 1480; AZD 3514; BGT 226; CXCR4 Mab; DB 67; Elisidepsin; Flanvotumab; G 3139; Ganitumab; GDC 0349; Girentuximab; GX 15 070; HSP 990; IMC 20D7S; IPI 926; Irofulven; KRN 330; LAS 41007; Lestaurtinib; LY 2584702; LY 573636; LY 900009; LY S6K1; MFGR 1877S; MGI 114; MINT 1526A; MLN 518; NMS 1116354; Obatoclax; Oblimersen; PLX 3603; PM 02734; RG 7256; RG 7444; RG 7594; RG 7603; SAR 103168; Saridegib; Tandutinib; Tasisulam; VER 82576; WX G250

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; A 1544750; AGS 1C 4D 4; AMUVATINIB; ANTINEOPLASTIC AGENT; AR 67; ASP 9521; AZD 3514; BGT 226; CEP 41601; CG 250; DB 67; E 7850; ELISIDEPSIN; FLANVOTUMAB; GANITUMAB; GDC 0349; GIRENTUXIMAB; HSP 990; IMC 20D 7S; IROFULVEN; KRN 330; LAS 41007; LESTAURTINIB; LY 2584702; LY 900009; MFGR 1877S; MINT 1526A; MLN 0518; NMS 1116354; NVP HSP 990; OBATOCLAX; OBLIMERSEN; PLX 3603; RG 7256; RG 7444; RG 7594; RG 7603; RO 5212054; S 6K 1; SAR 103168; SARIDEGIB; TANDUTINIB; TASISULAM; UNCLASSIFIED DRUG; VER 82576;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LYMPHOMA; BASAL CELL CARCINOMA; BONE CANCER; BRAIN CANCER; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GOVERNMENT; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MAST CELL LEUKEMIA; MELANOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOMA; MYELOPROLIFERATIVE DISORDER; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; PROSTATE CANCER; PSORIASIS; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; STOMACH CANCER; THROMBOCYTHEMIA; THYROID CANCER; TREATMENT FAILURE; TREATMENT WITHDRAWAL; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA;

ANTINEOPLASTIC AGENTS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS;

EID: 84887666327     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.847088     Document Type: Review

References (13)

1. Williams RJ. Discontinued drugs in 2011: oncology drugs. Expert Opin Investig Drugs 2013;22(1):9-34
2. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: The pharmaceutical industrys grand challenge. Nat Rev Drug Discov 2010;3):203-14.. Analysis of R&D productivity proposing specific strategies for improvement.
3. Available from: http://abstract.asco.org/AbstView-114-98676.html
4. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10(7):514-23.. Overview of the changing nature of clinical trial designs in cancer.
5. Workman P. How much gets there and what does it do The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9(11):891-902
6. Morgan P, Van Der Graff P, Arrowsmith J, et al. Can the flow of medicines be improved Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Disc Today 2012;17(9-10):419-24. Authors outline three pillars for the progression of early drug candidates.
7. Borden C, Dowlati A. Phase I trials of targeted anticancer drugs: A need to refoucus. Nat Rev Drug Discov 2012;11(12):889-90
8. Roth B, Krilov L, Adams S, et al. Clinical cancer advances 2012: Annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol 2013;31(1):131-61
9. Mullard A. 2012 FDA drug approvals. Nat Rev Drug Discov 2013;12(2):87-90
10. Ehmann F, Amati M, Salmonson T, et al. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude. Clin Pharm Ther 2013;93(5):425-32
11. Available from: http://www.businesswire. com/news/home/20120711006365/en/ Verastem-Acquires-Clinical-Stage-FAKInhibitor-Pfizer
12. Available from: http://www.prnewswire.com/news-releases/vlst- corporationannounces-in-licensing-agreement-withpfizer-for-anti-cd40- monoclonalantibody-168130076.html
13. Available from: http://www.ncats.nih.gov/research/reengineering/rescue- repurpose/therapeutic-uses/projects-2013.html